The novel family of Warbicin

Many cancer cells share with yeast a preference for fermentation over respiration, which is associated with overactive glucose uptake and breakdown, a phenomenon called the Warburg effect in cancer cells. The yeast

Informations de copyright

Copyright © 2024 Vanthienen, Fernández-García, Baietti, Claeys, Van Leemputte, Nguyen, Goossens, Deparis, Broekaert, Vlayen, Audenaert, Delforge, D’Amuri, Van Zeebroeck, Leucci, Fendt and Thevelein.

Déclaration de conflit d'intérêts

JT is owner and managing director of NovelYeast bv, which filed a patent application EP 21168650.6 on 15 April 2021 covering the use of the Warbicin® compounds for therapeutic purposes. NovelYeast has been granted registration of the term Warbicin® as Trademark. S-MF has received funding from Bayer Healthcare, Merck and BlackBelt Therapeutics and has consulted for Fund+. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.